<description>&lt;h1&gt;Episode Notes&lt;/h1&gt;
&lt;p&gt;Complicated UTIs just got a whole lot less complicated—or did they? Dr. Dana Bowers and Kyle Molina (@kcmolinaID) join Dr. Whitney Buckel to break down what’s new, what’s controversial, and what this means for your day‑to‑day antimicrobial decisions. Join us as we dig into the biggest updates, the evidence behind them, and the clinical pearls you won’t want to miss.&lt;/p&gt;
&lt;p&gt;References:&lt;/p&gt;
&lt;p&gt;Nelson Z, Aslan AT, Beahm NP, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement. JAMA Netw Open. 2024 Nov 4;7(11):e2444495.&lt;/p&gt;
&lt;p&gt;Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. Published July 17, 2025. &lt;a href="https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/" rel="nofollow"&gt;https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Kadry N, Natarajan M, Bein E, Kim P, Farley J. Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections. Clin Infect Dis 2023;76(10:1768-1775. &lt;a href="https://academic.oup.com/cid/article/76/10/1768/6980780" rel="nofollow"&gt;https://academic.oup.com/cid/article/76/10/1768/6980780&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;USCAST Oral cephalosporin STIC against S. aureus and E. coli meeting recording. &lt;a href="https://www.youtube.com/watch?v=HieaVFAC08s" rel="nofollow"&gt;https://www.youtube.com/watch?v=HieaVFAC08s&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;MacDougall C. A Cloudy Crystal Ball: Critically Assessing and Rethinking the Antibiogram. Clin Infect Dis. 2023;77(11):1501-1503. doi:10.1093/cid/ciad468&lt;/p&gt;
&lt;p&gt;Koehl J, Spolsdoff D, Negaard B, et al. Cephalosporins for Outpatient Pyelonephritis in the Emergency Department: COPY-ED Study. Ann Emerg Med. 2025;85(3):240-248. doi:10.1016/j.annemergmed.2024.10.013&lt;/p&gt;
&lt;p&gt;Dunne MW, Aronin SI, Das AF, et al. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023;76(1):78-88. doi:10.1093/cid/ciac704&lt;/p&gt;
&lt;p&gt;Learn more about the Society of Infectious Diseases Pharmacists: &lt;a href="https://protect2.fireeye.com/v1/url?k=4063f96c-1ff8c1be-4063b7ad-867b1e11f55a-4ebd02e8eaa2fcc2\&amp;amp;q=1\&amp;amp;e=caf63b63-0143-4fa9-a81b-8d3031af3116\&amp;amp;u=https%3A%2F%2Fsidp.org%2FAbout" rel="nofollow"&gt;https://sidp.org/About&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Instagram: @SIDPharm (&lt;a href="https://www.instagram.com/sidpharm/" rel="nofollow"&gt;https://www.instagram.com/sidpharm/&lt;/a&gt;) or @breakpointspodcast_sidp (&lt;a href="https://www.instagram.com/breakpointspodcast_sidp/" rel="nofollow"&gt;https://www.instagram.com/breakpointspodcast_sidp/&lt;/a&gt;)&lt;a href="https://www.instagram.com/breakpointspodcast_sidp/?hl=en" rel="nofollow"&gt;https://www.instagram.com/breakpointspodcast_sidp/?hl=en&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Facebook: &lt;a href="https://protect2.fireeye.com/v1/url?k=55e28658-0a79be8a-55e2c899-867b1e11f55a-8b838b5b24786aee\&amp;amp;q=1\&amp;amp;e=caf63b63-0143-4fa9-a81b-8d3031af3116\&amp;amp;u=https%3A%2F%2Fwww.facebook.com%2Fsidprx" rel="nofollow"&gt;https://www.facebook.com/sidprx&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;LinkedIn: &lt;a href="https://www.linkedin.com/company/sidp/" rel="nofollow"&gt;https://www.linkedin.com/company/sidp/&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: &lt;a href="https://sidp.org/Become-a-Member" rel="nofollow"&gt;https://sidp.org/Become-a-Member&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Listen to Breakpoints on &lt;a href="https://clicktime.symantec.com/3R8uEM1294vdh21uL7nDhi37VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DD0L0Q0-2A2f7TCFxVOgWn67jW1UJdXCNI8Kg8JiVOalanWSnv86s3-2A2feIgSCp0yFQqON7208n7OVg3dZANuq14i1FyBxNlUE-2A2fEuorj-2A2bQth-2A2f-2A2fdOz0-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJP8qJ0DM-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DnaJ94CqlnGko8PYcHx7P0a2ORkqJjTTXTXo3of9toOI%26e%3D" rel="nofollow"&gt;iTunes&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3UPSKiX9zWTmFRi5JvbYYuF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DuVw7WrCV3UsT9jQEoMx19bCJk8wSnOrHKsz-2A2fiDg5jIJz-2A2fPmlAAnjeQMczcZNKe65FwcZB1GSntOoUYpImtNgtdyfUUiYEctoWEc5okmtqjI-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJSsDRBjw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DiSHbkOT6yU9AfKVXVzZYoT6ihqn4rV7u2MtsJu0S4M0%26e%3D" rel="nofollow"&gt;Overcast&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3PoPyJU9wVY1CeG5JSoJ5TF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3D-2A2b6F4mrvzRMOPk-2A2ba-2A2bOlEsgbBTfXcxd55wOs9FeTrvlo4ldPpqgt3wD8-2A2fE3HTFftwPVPPM-2A2b6cPP8AXhMlUJL-2A2fVJcCllOYuUjVjRDDAWZ7AIEA-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJznOuBy8-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3D2k6k5CxoFMUsUIyOPzQO6SsDBdBx1NhRPK1AYDToK7g%26e%3D" rel="nofollow"&gt;Spotify&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3EzDPdcsg2aGkG24TqSDnQD7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DSMv1IUOMa6BBtA9x3UJdt0xL08TAUa63rcUQgIHTRk5z0skO9IEnaSqnkGdDVELU4LHF4xYo6n4QprSv5REh8CiWi24tVPHxui-2A2fuqe-2A2bSTcY-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgDogjBg-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dg4LAADo6MhO--d9qoDcdunhQOKfhr7JZ5QH6liBGX1w%26e%3D" rel="nofollow"&gt;Listen Notes&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3K5DQtmVxCMwmFfYTXFqors7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DVTJG9hRIZySdc5y4-2A2bhe4mxglJA6g9BcwePDuINOrGkp6xW-2A2brG3A2kq5lxBfriwS6WTOLOSeS4ISBSaSBKW5soT53zrLCvjBMOj4J11xQuOQ-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgJndlwc-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3D8zQ_WQmmq_ADO_yxCG2pCmfPHOXyBOt3Tvd8SLzw0ZM%26e%3D" rel="nofollow"&gt;Player FM&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3WCdXn4P2EkTbSZz3j2efpW7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DRuxN50dhXQmkw9mJ-2A2fIv1BwOldEM8lu6wJn-2A2bp-2A2bFH1TNKc-2A2fH8BYSR8y8gvYx02jfY5q57aOItrIB31hBXqNyioCeEXlh0uZxM-2A2b7yda7rBp-2A2bnQ-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJdwUkjek-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dph48oB1hX73YsIdjGLx2gcMvE6IA7KTEWazW2Gb_tGg%26e%3D" rel="nofollow"&gt;Pocket Casts&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3N9YYH2wFKdrWqgcDLyAPVP7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DbAcy2XwOPS5gzW3aqAHBDq3X-2A2fsXg3wyMXKklW6Ulzx0aRoyw2zdXn6m5fVIKUO608flwXYyAGXiN4hWz7mMsGMCS55chZ6PJz8V8gIyX8HI-2A3d-5F-5F-3BJSU-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgEBT6ts-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DPqs1eg6C2SkR8SgsjTAKF3jDx-0k2raeM9htByu_Ghs%26e%3D" rel="nofollow"&gt;Stitcher&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3QxZKFTBT9VdfKHPUjpQykP7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DXRXFG9Dw8bLzFpLbMrEfM96UuBur0JW9QvgSd3FZ4RzNUy-2A2bAuHT4n48P5fT3624i4mKWOBMJ2c6glolIQP9Z0iI7LjIz87QyZ5cKKJCKaNc-2A3d-5F-5F-3BJSU-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJErop2PU-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DM0gZOkT6pxtYnqMcQRd_VtlxUl-5PqROGqAmvy3qmMc%26e%3D" rel="nofollow"&gt;Google Play&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3HAZ1dAKjokvr2fVP1FEFmZ7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DHM5q-2A2bqjVNHXHSuzhQfgDHnfYMTayJY5I54xK583XQlZuSY-2A2fiukAdy7bGkpDwwp4DsXAS8nTuZi2kow5ilRLCsjmfJitQC61ab1gmhUelJY4-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJpiKf8vY-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dl98Xj6atbJE3Bl9nQFR0NxeCSObWEBXn2QRprS9VAPM%26e%3D" rel="nofollow"&gt;TuneIn&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3Uc5sj35HuHzBtN9qsZELaz7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DGDsckAp3VJZvS-2A2b-2A2bFQBnNnris8ulgVAn4tAgxp4bAnDy-2A2bDLqT7z-2A2btergfEsE7sz7-2A2fi9-2A2bFF54K4LSozTCeCmh8VOosKkqijPiN5VAKc79XwEk-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJoMTwltw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DOqwdj1qqIUl3AHO7g0LP6TxXzSXeXUX4Ce_Sv_hRfyw%26e%3D" rel="nofollow"&gt;Blubrry&lt;/a&gt;, &lt;a href="https://clicktime.symantec.com/3Dfmv5CECYNRhGAwqZ5sQdY7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DQ7W-2A2bjxudl-2A2biTqflXrhVsrXi0r-2A2fptIhwKQytXBX17a9V2Op9GnTA1RTRGL19e54xgVdZSW-2A2bJeLiR7wWXkwDiSYgglUPHsNsGqAu6xuhXPp6o-2A3d-5F-5F-3BJSUlJSU-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJzCo9rGw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DnBRVi03Hc0KelEEqohO2GHfC96p04Pkm8F2eHsswsZY%26e%3D" rel="nofollow"&gt;RadioPublic&lt;/a&gt;, or by using our RSS feed: &lt;a href="https://sidp.pinecast.co/" rel="nofollow"&gt;https://sidp.pinecast.co/&lt;/a&gt;&lt;/p&gt;</description>

Breakpoints

Society of Infectious Diseases Pharmacists

#132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy

MAR 13, 202668 MIN
Breakpoints

#132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy

MAR 13, 202668 MIN

Description

<h1>Episode Notes</h1> <p>Complicated UTIs just got a whole lot less complicated—or did they? Dr. Dana Bowers and Kyle Molina (@kcmolinaID) join Dr. Whitney Buckel to break down what’s new, what’s controversial, and what this means for your day‑to‑day antimicrobial decisions. Join us as we dig into the biggest updates, the evidence behind them, and the clinical pearls you won’t want to miss.</p> <p>References:</p> <p>Nelson Z, Aslan AT, Beahm NP, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement. JAMA Netw Open. 2024 Nov 4;7(11):e2444495.</p> <p>Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. Published July 17, 2025. <a href="https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/" rel="nofollow">https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/</a></p> <p>Kadry N, Natarajan M, Bein E, Kim P, Farley J. Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections. Clin Infect Dis 2023;76(10:1768-1775. <a href="https://academic.oup.com/cid/article/76/10/1768/6980780" rel="nofollow">https://academic.oup.com/cid/article/76/10/1768/6980780</a></p> <p>USCAST Oral cephalosporin STIC against S. aureus and E. coli meeting recording. <a href="https://www.youtube.com/watch?v=HieaVFAC08s" rel="nofollow">https://www.youtube.com/watch?v=HieaVFAC08s</a></p> <p>MacDougall C. A Cloudy Crystal Ball: Critically Assessing and Rethinking the Antibiogram. Clin Infect Dis. 2023;77(11):1501-1503. doi:10.1093/cid/ciad468</p> <p>Koehl J, Spolsdoff D, Negaard B, et al. Cephalosporins for Outpatient Pyelonephritis in the Emergency Department: COPY-ED Study. Ann Emerg Med. 2025;85(3):240-248. doi:10.1016/j.annemergmed.2024.10.013</p> <p>Dunne MW, Aronin SI, Das AF, et al. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023;76(1):78-88. doi:10.1093/cid/ciac704</p> <p>Learn more about the Society of Infectious Diseases Pharmacists: <a href="https://protect2.fireeye.com/v1/url?k=4063f96c-1ff8c1be-4063b7ad-867b1e11f55a-4ebd02e8eaa2fcc2\&amp;q=1\&amp;e=caf63b63-0143-4fa9-a81b-8d3031af3116\&amp;u=https%3A%2F%2Fsidp.org%2FAbout" rel="nofollow">https://sidp.org/About</a></p> <p>Instagram: @SIDPharm (<a href="https://www.instagram.com/sidpharm/" rel="nofollow">https://www.instagram.com/sidpharm/</a>) or @breakpointspodcast_sidp (<a href="https://www.instagram.com/breakpointspodcast_sidp/" rel="nofollow">https://www.instagram.com/breakpointspodcast_sidp/</a>)<a href="https://www.instagram.com/breakpointspodcast_sidp/?hl=en" rel="nofollow">https://www.instagram.com/breakpointspodcast_sidp/?hl=en</a></p> <p>Facebook: <a href="https://protect2.fireeye.com/v1/url?k=55e28658-0a79be8a-55e2c899-867b1e11f55a-8b838b5b24786aee\&amp;q=1\&amp;e=caf63b63-0143-4fa9-a81b-8d3031af3116\&amp;u=https%3A%2F%2Fwww.facebook.com%2Fsidprx" rel="nofollow">https://www.facebook.com/sidprx</a></p> <p>LinkedIn: <a href="https://www.linkedin.com/company/sidp/" rel="nofollow">https://www.linkedin.com/company/sidp/</a></p> <p>SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: <a href="https://sidp.org/Become-a-Member" rel="nofollow">https://sidp.org/Become-a-Member</a></p> <p>Listen to Breakpoints on <a href="https://clicktime.symantec.com/3R8uEM1294vdh21uL7nDhi37VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DD0L0Q0-2A2f7TCFxVOgWn67jW1UJdXCNI8Kg8JiVOalanWSnv86s3-2A2feIgSCp0yFQqON7208n7OVg3dZANuq14i1FyBxNlUE-2A2fEuorj-2A2bQth-2A2f-2A2fdOz0-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJP8qJ0DM-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DnaJ94CqlnGko8PYcHx7P0a2ORkqJjTTXTXo3of9toOI%26e%3D" rel="nofollow">iTunes</a>, <a href="https://clicktime.symantec.com/3UPSKiX9zWTmFRi5JvbYYuF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DuVw7WrCV3UsT9jQEoMx19bCJk8wSnOrHKsz-2A2fiDg5jIJz-2A2fPmlAAnjeQMczcZNKe65FwcZB1GSntOoUYpImtNgtdyfUUiYEctoWEc5okmtqjI-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJSsDRBjw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DiSHbkOT6yU9AfKVXVzZYoT6ihqn4rV7u2MtsJu0S4M0%26e%3D" rel="nofollow">Overcast</a>, <a href="https://clicktime.symantec.com/3PoPyJU9wVY1CeG5JSoJ5TF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3D-2A2b6F4mrvzRMOPk-2A2ba-2A2bOlEsgbBTfXcxd55wOs9FeTrvlo4ldPpqgt3wD8-2A2fE3HTFftwPVPPM-2A2b6cPP8AXhMlUJL-2A2fVJcCllOYuUjVjRDDAWZ7AIEA-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJznOuBy8-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3D2k6k5CxoFMUsUIyOPzQO6SsDBdBx1NhRPK1AYDToK7g%26e%3D" rel="nofollow">Spotify</a>, <a href="https://clicktime.symantec.com/3EzDPdcsg2aGkG24TqSDnQD7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DSMv1IUOMa6BBtA9x3UJdt0xL08TAUa63rcUQgIHTRk5z0skO9IEnaSqnkGdDVELU4LHF4xYo6n4QprSv5REh8CiWi24tVPHxui-2A2fuqe-2A2bSTcY-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgDogjBg-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dg4LAADo6MhO--d9qoDcdunhQOKfhr7JZ5QH6liBGX1w%26e%3D" rel="nofollow">Listen Notes</a>, <a href="https://clicktime.symantec.com/3K5DQtmVxCMwmFfYTXFqors7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DVTJG9hRIZySdc5y4-2A2bhe4mxglJA6g9BcwePDuINOrGkp6xW-2A2brG3A2kq5lxBfriwS6WTOLOSeS4ISBSaSBKW5soT53zrLCvjBMOj4J11xQuOQ-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgJndlwc-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3D8zQ_WQmmq_ADO_yxCG2pCmfPHOXyBOt3Tvd8SLzw0ZM%26e%3D" rel="nofollow">Player FM</a>, <a href="https://clicktime.symantec.com/3WCdXn4P2EkTbSZz3j2efpW7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DRuxN50dhXQmkw9mJ-2A2fIv1BwOldEM8lu6wJn-2A2bp-2A2bFH1TNKc-2A2fH8BYSR8y8gvYx02jfY5q57aOItrIB31hBXqNyioCeEXlh0uZxM-2A2b7yda7rBp-2A2bnQ-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJdwUkjek-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dph48oB1hX73YsIdjGLx2gcMvE6IA7KTEWazW2Gb_tGg%26e%3D" rel="nofollow">Pocket Casts</a>, <a href="https://clicktime.symantec.com/3N9YYH2wFKdrWqgcDLyAPVP7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DbAcy2XwOPS5gzW3aqAHBDq3X-2A2fsXg3wyMXKklW6Ulzx0aRoyw2zdXn6m5fVIKUO608flwXYyAGXiN4hWz7mMsGMCS55chZ6PJz8V8gIyX8HI-2A3d-5F-5F-3BJSU-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgEBT6ts-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DPqs1eg6C2SkR8SgsjTAKF3jDx-0k2raeM9htByu_Ghs%26e%3D" rel="nofollow">Stitcher</a>, <a href="https://clicktime.symantec.com/3QxZKFTBT9VdfKHPUjpQykP7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DXRXFG9Dw8bLzFpLbMrEfM96UuBur0JW9QvgSd3FZ4RzNUy-2A2bAuHT4n48P5fT3624i4mKWOBMJ2c6glolIQP9Z0iI7LjIz87QyZ5cKKJCKaNc-2A3d-5F-5F-3BJSU-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJErop2PU-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DM0gZOkT6pxtYnqMcQRd_VtlxUl-5PqROGqAmvy3qmMc%26e%3D" rel="nofollow">Google Play</a>, <a href="https://clicktime.symantec.com/3HAZ1dAKjokvr2fVP1FEFmZ7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DHM5q-2A2bqjVNHXHSuzhQfgDHnfYMTayJY5I54xK583XQlZuSY-2A2fiukAdy7bGkpDwwp4DsXAS8nTuZi2kow5ilRLCsjmfJitQC61ab1gmhUelJY4-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJpiKf8vY-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dl98Xj6atbJE3Bl9nQFR0NxeCSObWEBXn2QRprS9VAPM%26e%3D" rel="nofollow">TuneIn</a>, <a href="https://clicktime.symantec.com/3Uc5sj35HuHzBtN9qsZELaz7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DGDsckAp3VJZvS-2A2b-2A2bFQBnNnris8ulgVAn4tAgxp4bAnDy-2A2bDLqT7z-2A2btergfEsE7sz7-2A2fi9-2A2bFF54K4LSozTCeCmh8VOosKkqijPiN5VAKc79XwEk-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJoMTwltw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DOqwdj1qqIUl3AHO7g0LP6TxXzSXeXUX4Ce_Sv_hRfyw%26e%3D" rel="nofollow">Blubrry</a>, <a href="https://clicktime.symantec.com/3Dfmv5CECYNRhGAwqZ5sQdY7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DQ7W-2A2bjxudl-2A2biTqflXrhVsrXi0r-2A2fptIhwKQytXBX17a9V2Op9GnTA1RTRGL19e54xgVdZSW-2A2bJeLiR7wWXkwDiSYgglUPHsNsGqAu6xuhXPp6o-2A3d-5F-5F-3BJSUlJSU-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJzCo9rGw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DnBRVi03Hc0KelEEqohO2GHfC96p04Pkm8F2eHsswsZY%26e%3D" rel="nofollow">RadioPublic</a>, or by using our RSS feed: <a href="https://sidp.pinecast.co/" rel="nofollow">https://sidp.pinecast.co/</a></p>